This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Smith & Nephew (SNN) Partners InfuSystem for Renasys Edge
by Zacks Equity Research
Smith & Nephew (SNN) inks a three-year agreement with InfuSystem (INFU) to distribute its RENASYS EDGE negative pressure wound therapy system.
Smith & Nephew (SNN), HOPCo to Enhance Musculoskeletal Care
by Zacks Equity Research
Smith & Nephew (SNN) announces a collaboration with HOPCo to focus on enhancing solutions for ASC customers, physicians, and patients through the latter's digital health and analytics platforms.
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure
by Zacks Equity Research
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.
Smith+Nephew (SNN) Expands in Australia With New Alliance
by Zacks Equity Research
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
by Zacks Equity Research
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew (SNN) New Buyout Expands Sports Medicine Suite
by Zacks Equity Research
Smith & Nephew (SNN) will pay an initial cash consideration of $180 million at closure, with an additional $150 million based on financial performance to acquire CartiHeal.
The Zacks Analyst Blog Highlights Abbott Laboratories, Koninklijke Philips and Smith & Nephew
by Zacks Equity Research
Abbott Laboratories, Koninklijke Philips and Smith & Nephew are included in this Analyst Blog.
3 Medical Product Stocks With Solid Dividend Yield: ABT & Others
by Indrajit Bandyopadhyay
Here we pick three stocks, Abbott Laboratories (ABT), Koninklijke Philips (PHG) and Smith & Nephew SNATS (SNN) from the Medical - Products industry, with a solid five-year dividend growth history.
Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Koninklijke Philips (PHG) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew (SNN) Loses -5.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers
by Zacks Equity Research
Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.
Should Value Investors Buy National Vision (EYE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Perrigo (PRGO) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What Makes Smith & Nephew (SNN) a New Buy Stock
by Zacks Equity Research
Smith & Nephew (SNN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.